About, Dr Vanita Noronha (Geriatric Oncologist in Mumbai)
Dr. Vanita Noronha is one of the most esteemed & renowned Geriatric Oncology in Mumbai with an overall experience of 25 years in this field. She is currently practicing at Tata Memorial Hospital, Parel, Mumbai. Dr. Vanita Noronha is constantly working on new treatments for significant improvement in survival rates by providing access to affordable and effective treatment plans.
Specialization
Dr. Vanita Noronha is a well-known medical specialist in the following interventions –
- Medical Oncology
- Blood Cancer Treatment
- Bone Marrow Transplant
- Immunotherapy
- Chemotherapy
- Prostate Cancer
- Metastasis
- Cancer Biology
- Geriatric Oncology
- Internal Medicine
Education
- Seth G.S. Medical College, MBBS (1998)
- University at Buffalo Residency, Internal Medicine (1999-2002)
- Yale – New Haven Medical Center Fellowship, Hematology and Medical Oncology (2002-2005)
Career
Dr. Vanita Noronha is a certified Medical Oncologist contributed to several hospitals and institutions from
- Senior fellow in Medical Oncology and Hematology at Yale Cancer Center, Yale University, New Haven, Connecticut, USA
- Professor and Medical Oncologist at Tata Memorial Hospital, Mumbai
- Editor-in-chief at Cancer Research Statistics and Treatment
Publications
Dr. Vanita Noronha has authored around 612 publications. Some recent publications are mentioned below
-
Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
- Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation
- Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings
- Epidemiological Trend of Esophageal Cancer at a Tertiary Cancer Center in Mumbai, India, Over the Past 15 Years
- ROS1 positive non small cell lung cancer
- Immune checkpoint inhibitors: Promising but still inaccessible treatment option for patients with head-and- neck cancer in India
- 361P 8-year long term survival status in a phase III randomized study in EGFR mutated advanced lung cancer patients in the first-line
- Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study
- 391P Demographics, treatment patterns and clinical outcomes in ROS1-positive non-small cell lung cancer: A referral tertiary cancer centre experience from a low-middle income country
- Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
- Leptomeningeal metastasis from non-small cell lung cancer – a post-hoc analysis from four randomised clinical trials
- Results of phase 3 randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation.
Dr. Vanita Noronha is a skilled and experienced doctor and her findings are significantly beneficial in the improvement of major illnesses and disorders. The findings specifically support pembrolizumab plus platinum-based chemotherapy, and pembrolizumab monotherapy as a new treatment for curing cancer effectively. She started using this information on patients with metastatic disease that cannot undergo radial therapy. If the disease is of less than 6 months then she provides platinum-based therapy and if the disease is more than 6 months then platinum along with monotherapies are provided affordably. Lastly, for patients with severe symptoms, she will prescribe platinum along with chemotherapy for the best outcome. Dr. Vanita’s objective is to reach out to patients through accurate guidance and support by means of advanced treatment options to help in their journey to cure.
Submit your review | |